Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03316781
Other study ID # HLX03-Ps03
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date October 27, 2017
Est. completion date April 22, 2019

Study information

Verified date May 2022
Source Shanghai Henlius Biotech
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, randomized, double-blind, positive drug parallel-group controlled clinical study in China to evaluate efficacy, safety, tolerability and immunogenicity of HLX03 and adalimumab (Humira) in subjects with moderate to severe plaque psoriasis. This study will recruit 216 subjects (18-75 years old, male and female) with moderate to severe plaque psoriasis. The 216 subjects will be randomly assigned per 1:1 ratio into the following two treatment groups (HLX03 OR Adalimumab). The study will be conducted in three periods, including the screening period, treatment period and follow-up period. For each participating subjects, the maximal length of the study will be 56 weeks (including up to four weeks of screening time).


Recruitment information / eligibility

Status Completed
Enrollment 262
Est. completion date April 22, 2019
Est. primary completion date July 15, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Able and willing to give written informed consent. 2. Men or women is =18 and = 75 years of age at time of screening. 3. Stable moderate to severe plaque psoriasis for at least 6 months before Screening. 4. Moderate to severe psoriasis as defined at Baseline by: BSA of = 10% involvement at the Baseline visit. PGA score of = 3 at the Baseline visit. PASI score of = 12 at the Baseline visit. 5. Acceptable to systemic therapy, as judged by the investigator. 6. Previously received at least one traditional psoriasis treatment (for example, methotrexate, cyclosporine A, psoralen plus UVA or UVB, tretinoin, Chinese medicine, etc.), and was insensitive, intolerant, contraindicated to, or failed the treatment, as judged by the investigator. 7. At time of screening, lab tests have to meet the following: 1. Hemoglobin = 90 g/L 2. WBC = 3.5 × 10^9/L 3. Platelets = 100 × 10^9/L 4. Serum creatinine =1.5 × upper limit of normal (ULN) 5. AST and ALT =2 × ULN 8. For women of child-bearing age, a negative serum pregnancy test during screening, and a negative urine pregnancy test at baseline. 9. During the study to 150 days after the last dose of study medicine, subjects should use effective contraceptive measures 10. Subject is willing and able to comply with the visit schedule and other requirements of the study. Exclusion Criteria: 1. At screening visit, subjects with erythrodermic psoriasis, pustule psoriasis, bit type psoriasis, drug-induced psoriasis, other skin lesions (such as eczema), other systemic autoimmune inflammatory lesions, which may affect the efficacy evaluation of the treatment. 2. The subject has surgery plan during the study period (excluding surgery that is related to the study disease), except that there will be no increased risk for the subjects or no influence on the study treatment or adherence to the study as judged by the investigator. 3. Participants were given the following treatment, or will be required to receive the following treatment during the study period: 1. The use of topical drugs within the first two weeks before screening; 2. The use of UVA and/or UVB treatment, and non-biological drugs (such as methotrexate, cyclosporin, tretinoin, traditional Chinese medicine, proprietary Chinese medicine, etc) within the first four weeks before screening; 3. In the first 4 weeks before screening, the use of Etanercept or Etanercept; in the first 12 weeks before screening, the use of other biological agents 4. Subjects had live vaccination in the first four weeks before screening, or have the intention to receive live vaccination during the study period. 5. Subjects with history of mycobacterium tuberculosis infection, or with active tuberculosis, or with latent tuberculosis, or with suspected tuberculosis infection judged by clinical phenotypes. 6. Anti-HIV antibody positive, or antibody positive for treponema pallidum, or anti-HCV antibody positive, or HBV HBsAg and/or HBcAb positive at screening. 7. Accompanying active infection or history: 1. Within 4 weeks before screening, systemic anti-infection treatment; 2. Within 8 weeks before screening, severe infection with hospitalization or intravenous anti-infection treatment; 3. Recurrent, chronic, or other active infections, which may increase the study risk as evaluated by the investigator. 8. Known malignancy or history of malignancy (except for the following: in situ skin squamous carcinoma after thorough treatment with no sign of recurrence, basal cell carcinoma, cervical cancer in situ, or skin squamous carcinoma at least five years prior to randomization with no signs of recurrence after treatment). 9. Ongoing, severe, progressive, or uncontrolled diseases, including but not limited to diseases at the endocrine system, blood system, urinary system, liver and gallbladder, respiratory system, nervous system, cardiovascular system, gastrointestinal system or infectious diseases, with increased risk to participate the study as assessed by the investigator. 10. The subjects with active neuropathies, such as multiple sclerosis, Guillain-Barre Syndrome, optic neuritis, transverse myelitis, or neurological symptoms suggestive of the demyelinating diseases of the central nervous system. 11. Moderate to severe heart failure (NYHA III/IV) 12. History of allergic reactions to the active components of the study drugs (HLX03 and adalimumab (Humira®)) and their formulation gradients, or medicines belonging to the same pharmacology and biological category. 13. Participated in another study and received an experimental related drugs within the previous 3 months before screening. 14. Pregnant or lactating women. 15. History of alcohol or substance abuse or dependence, mental disorders. 16. Any condition that will lead to no treatment benefit or affect efficacy evaluation, as judged by the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
HLX03
80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.
adalimumab
80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.

Locations

Country Name City State
China Peking University People's Hospital Beijing

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Henlius Biotech

Country where clinical trial is conducted

China, 

References & Publications (1)

Cai L, Li L, Cheng H, Ding Y, Biao Z, Zhang S, Geng S, Liu Q, Fang H, Song Z, Lu Y, Li S, Guo Q, Tao J, He L, Gu J, Yang Q, Han X, Gao X, Deng D, Li S, Wang Q, Zhu J, Zhang J. Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Modera — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage improvement of PASI from baseline to Week 16 Percent improvement of PASI from baseline to Week 16 will be calculated as the following formula: (PASI baseline-PASI Week 16) x 100% /PASI baseline Week 16
Secondary PASI 75 response 75% or greater improvement in PASI score Week 4, 8, 12, 16, 24, 32, 50
Secondary PASI percent improvement Week 4, 8, 12, 24, 32, 50
Secondary Static Physician's Global Assessment (sPGA) responses (with 0 or 1 being a positive result) Week 4, 8, 12, 16, 24, 32, 50
Secondary Change of DLQI from baseline Week 4, 8, 12, 16, 24, 32, 50
See also
  Status Clinical Trial Phase
Completed NCT01194219 - Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis Phase 3
Recruiting NCT06030076 - A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
Completed NCT04263610 - Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy Phase 4
Completed NCT02601469 - Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis Phase 2
Completed NCT05600036 - A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis Phase 2
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03614078 - A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis Phase 2
Not yet recruiting NCT05036889 - A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes. N/A
Completed NCT04603027 - A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis Phase 2
Completed NCT03638258 - The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis Phase 2
Completed NCT02881346 - Efficacy and Tolerability of Enstilar® in Daily Practice
Recruiting NCT02611349 - Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis Phase 3
Completed NCT02251678 - Evaluate the Effect of Elimune Capsules Phase 1
Completed NCT01987843 - Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis Phase 2
Terminated NCT01708629 - Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects Phase 3
Completed NCT01230138 - Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis Phase 2
Withdrawn NCT00747032 - To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis Phase 3
Completed NCT00581100 - Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Phase 4
Suspended NCT01228656 - Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate Phase 2
Completed NCT00540618 - A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis Phase 2